Display Settings:

Items per page

Results: 6

1.
Figure 2

Figure 2. From: A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life.

(a) Receptor-binding ELISA results for rhGH(•; dashed line), XTEN1–rhGH (▪), and VRS-317 (▪). (b) In vitro cell-based potency assay results for rhGH (•; dashed line) and VRS-317 (▪) [relative fluorescence units (RFU) measuring number of viable cells].

Jeffrey L Cleland, et al. J Pharm Sci. 2012 August;101(8):2744-2754.
2.
Figure 3

Figure 3. From: A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life.

(a) Pharmacokinetics in rats after subcutaneous (s.c.) administration of 0.3 mg/kg (13.5 nmol/kg) rhGH (•), 1.5 mg/kg (13.2 nmol/kg) of XTEN1–rhGH (▪; dashed line), or 1.5 mg/kg (12.6 nmol/kg) of VRS-317 (▪). (b) The pharmacokinetics of XTEN1–rhGH (▪; dashed line; 44.1 nmol/kg) and VRS-317 (▪, 42.1 nmol/kg) after a single 5 mg/kg s.c. injection in adult cynomolgus monkeys.

Jeffrey L Cleland, et al. J Pharm Sci. 2012 August;101(8):2744-2754.
3.
Figure 4

Figure 4. From: A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life.

(a) Pharmacokinetics of 1.5 mg/kg (12.6 nmol/kg) of VRS-317 in cynomolgus monkeys dosed either intravenously (i.v.; ▵), subcutaneously (s.c.; ▴) or intramuscularly (i.m.; ▪). (b) Same results shown for first 24 h after dosing.

Jeffrey L Cleland, et al. J Pharm Sci. 2012 August;101(8):2744-2754.
4.
Figure 5

Figure 5. From: A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life.

(a) Pharmacokinetics of VRS-317 dosed s.c. at 0.4 (□) or 1.4 (▪) mg/kg (3.4 or 11.8 nmol/kg) VRS-317 every 28 days in juvenile cynomolgus monkeys (genders combined). (b) Pharmacokinetics of 0.05 mg/(kg day) rhGH dosed s.c. in juvenile cynomolgus monkeys after first (Day 1; ▪) and last dose (Day 28; •).

Jeffrey L Cleland, et al. J Pharm Sci. 2012 August;101(8):2744-2754.
5.
Figure 6

Figure 6. From: A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life.

IGF-I (a) and IGFBP-3 (b) changes from baseline in juvenile cynomolgus monkeys after administration of placebo (×), 0.05 mg/(kg day) rhGH for 28 days (▴; 1.4 mg/kg rhGH; 64 nmol/kg), 0.40 (□) or 1.4 mg/kg (▪; 3.4 or 11.8 nmol/kg, respectively) VRS-317 as single s.c. injection.

Jeffrey L Cleland, et al. J Pharm Sci. 2012 August;101(8):2744-2754.
6.
Figure 1

Figure 1. From: A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life.

(a) SDS-PAGE of 2, 5, and 10 μg of VRS-317 compared with a molecular weight marker. (b) Size exclusion HPLC analysis of VRS-317 (solid curve) compared with a set of globular molecular weight standards (dashed curve, Bio-Rad Laboratories, Hercules, California). The standard includes thyroglobulin 670 kDa, gamma-globulin 158 kDa, ovalbumin 44 kDa, myoglobin 17 kDa, and vitamin B12 1.35 kDa. The formulation buffer for VRS-317 elutes at 25 mL.

Jeffrey L Cleland, et al. J Pharm Sci. 2012 August;101(8):2744-2754.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk